Congrats to our client, Epitomee Medical Ltd., on their successful IPO on the Tel Aviv Stock Exchange. As part of the IPO, Epitomee raised 162 million NIS for an evaluation of 632 million NIS.
Epitomee’s groundbreaking technology allows a patient to receive biological treatment directly to the digestive system, by swallowing a capsule containing small medical devices, instead of intravenously or by injections.
Partner Itshak Cohen-Yehonatan and Associate Omer Weiss represented Epitomee Medical in the IPO.